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1. Introduction  
Pancreatic cancer is the fourth leading cause of cancer mortality in both men and women. 
Approximately 32,000 Americans each year will develop and also die from this disease . 
Despite aggressive surgical and medical management, the mean life expectancy is 
approximately 15–18 months for patients with local and regional disease, and 3–6 months 
for patients with metastatic disease 1-2. Even in case of radical surgery it is associated with a 
poor prognosis and a 5-year survival rate of less than 4%. Early detection methods are under 
development but do not yet exist in practice for pancreatic cancer. Therefore, most patients 
present with advanced disease that cannot be cured by surgery (pancreaticoduodenectomy). 
Clinically, pancreatic cancer is characterized by rapid tumor progression, early 
metastatization and unresponsiveness to most conventional treatment modalities. In a 
recent analysis using a database from 1973 to 2003 based on modeled period analysis, 5-year 
survival of pancreatic cancer patients was 7.1% and 10-year survival was below 5%3. The 
survival rate is apparently related to the disease stage with a low rate at 1.6–3.3% among 
patients with distant metastases. Curative resection remains the most important factor 
determining outcome for resectable tumors. However, the resection rate for pancreatic 
carcinoma is only 10% and the overall five-year survival rate after resection is still only 10 to 
20%.  Early diagnosis and effective treatment to control the advanced stages of disease may 
prolong the survival rate of pancreatic cancer. Otherwise pancreatic cancer remains a 
disease with high mortality despite numerous efforts that have been made to improve its 
survival rates.  
In developing cancer immunotherapy, the following aims must be considered: (1) detection 
of immune response to autologous tumor cells, (2) identification of tumor antigens and 
analysis of the immune responses in patients, (3) analysis of tumor escape mechanisms and 
development of methods to overcome them, and (4) development of a more efficient 
immune intervention system by way of animal model experiments and clinical trials. 
Identification of tumor antigens in the first objective is important because it subsequently 
allows their use not only as targets for immunotherapy in a more immunogenic form but 
also enables quantitative and qualitative monitoring of immune responses to tumor cells 
during immunotherapy. In many animal tumors and in human melanoma, T cells play an 
www.intechopen.com
 Pancreatic Cancer – Clinical Management 
 
138 
important role in in vivo tumor rejection. Because of their expression of MHC class I, CD8+ 
T cells are integral in the eradication of most solid tumors. However, CD4+ T cells are also 
important in the induction and maintenance of final effectors, such as CD8+ T cells and 
macrophages, as well as for the accumulation of CD8+ T cells in tumor tissues. Thus, we are 
applying various methods to identify human tumor antigens recognized by T cells. 
Immunotherapy has an advantage over radiation therapy and chemotherapy because it can 
act specifically against the tumor without damaging normal tissue. Immunotherapeutic 
approaches to PC have included the use of monoclonal antibodies 47, cytokines 8, vaccine 9 
and lymphokine activated killer (LAK) cells (10).  
2. Immune surveillance and tumour evasion 
The extraordinary features of the immune system make it possible to discern self from non-
self. However, most human cancers, and pancreatic cancer in particular, are known to be 
poorly immunogenic, as crucial somatic genetic mutations can generate pancreatic cancer 
proteins that are essentially altered self proteins. Furthermore, promising 
immunotherapeutic approaches that have been used for relatively immunogenic cancers 
such as melanoma have met with variable success6. These observations have revealed that 
for tumours to form and progress, they must develop local and/or systemic mechanisms 
that subsequently allow them to escape the normal surveillance mechanisms of the intact 
immune system. Immune-based therapies must therefore incorporate at least one agent 
against a pancreatic cancer target as well as one or more agents that will modify both local 
and systemic mechanisms of pancreatic-cancer-induced IMMUNE TOLERANCE.  
It is now clear that both local characteristics of the tumour microenvironment as well as 
systemic factors are important for the immune evasion of tumours. For example, T-cell 
recognition of pancreatic tumours might be inhibited or suppressed due to the 
downregulation of human leukocyte antigen (HLA) CLASS I tumour-antigen complexes on 
tumour cells by a range of intracellular mechanisms4, 7 — upregulation of immune-
inhibition molecules11, 12, 13, 14, 15, 16, 17, loss of immune-regulation signals15, 16, 17, 18, 19, 20, 21, 22, 23, 
24, 25, 26, 27, 28, 29, 30, defects in immune-cell tumour localization31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 
45, 46, 47, 48, 49, 50, 51 and loss of co-stimulatory molecules52, 53, 54, 55, 56, 57. Such alterations within a 
tumour cell would not be unexpected, as they have unstable genomes. The local 
inflammatory reaction is also an important triggering event in the recruitment of 
professional ANTIGEN-PRESENTING CELLS (APCs) and effector cells, such as T cells and 
NATURAL KILLER (NK) CELLS, to the tumour site. However, pancreatic tumour cells 
express a range of proteins that inhibit pro-inflammatory cytokines and DENDRITIC CELL 
(DC) MATURATION58, 59, 60. 
In addition, the numbers of CD4+CD25+ T regulatory (TReg) CELLS — a subset of T cells that 
are known to be important in the suppression of self-reactive T cells (peripheral 
tolerance) — accumulate in pancreatic tumours61, 62, 63. Although these cells are thought to be 
activated during the immunization process, TReg cells seem to localize to tumour sites. 
Tumour production of the chemokine CCL22 probably attracts the TReg cells by interacting 
with the CCR4 receptor that is expressed by these cells64. 
Other important elements in regulating the T-cell recognition of pancreatic tumours are the 
inhibitory pathways, known as 'immunological checkpoints'. Immunological checkpoints 
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serve two purposes. One is to help generate and maintain self-tolerance, by eliminating T 
cells that are specific for self-antigens. The other is to restrain the amplitude of normal T-cell 
responses so that they do not 'overshoot' in their natural response to foreign pathogens. The 
prototypical immunological checkpoint is mediated by the cytotoxic-T-lymphocyte-
associated protein 4 (CTLA4) counter-regulatory receptor that is expressed by T cells when 
they become activated15, 23. CTLA4 binds two B7-FAMILY members on the surface APCs — 
B7.1 (also known as CD80) and B7.2 (also known as CD86) — with roughly 20-fold higher 
affinity than the T-cell surface protein CD28 binds these molecules. CD28 is a co-stimulatory 
receptor that is constitutively expressed on naive T cells. Because of its higher affinity, 
CTLA4 out-competes CD28 for B7.1/B7.2 binding, resulting in the downmodulation of T-
cell responses20. 
A range of B7-family members interact with co-stimulatory and counter-regulatory 
inhibitory receptors on T cells. Two recently discovered B7-family members, B7-H1 (also 
known as PD-L1) and B7-DC (also known as PD-L2) also seem to interact with T-cell co-
stimulatory and counter-regulatory inhibitory receptors18, 29, 30. PD-L1, which is upregulated 
on T cells when they become activated, seems to control a counter-regulatory 
immunological checkpoint when it binds PD-1  26,28,29. Activating receptors for B7-DC and 
B7-H1 have not yet been definitively identified. B7-DC is expressed on DCs, and is likely to 
have a co-stimulatory role in increasing activation of naive or resting T cells. In contrast to 
B7.1, B7.2 and B7-DC, B7-H1 is also expressed on several peripheral tissues and on many 
tumours, including pancreatic tumours30. 
Another new B7-family member, B7-H4, seems to mediate a predominantly inhibitory 
function in the immune system14. Recent data indicate that pancreatic tumours also express 
B7-H4 (D.L. and E.M.J., manuscript in preparation), and both B7-H1 and B7-H4 probably 
protect tumours from immune-system attack. Preclinical studies have already demonstrated 
that it is possible to downregulate B7-H1 signalling in mice, improving the antitumour 
response to vaccination18. Monoclonal antibodies that downregulate B7-H1 and B7-H4 are 
currently in clinical development. These antibodies will probably begin clinical testing in 
patients with pancreatic cancer within 2 to 3 years.  
3. Cancer immunotherapy protocols 
Clinical trials using various immunotherapies, active immunization with tumor antigens, or 
tumor cell–derived products, and adoptive immunotherapy using antitumor immune cells 
were conducted in various cancers, most extensively in melanoma, and tumor regression 
was observed in some patients. Active Immunization Immunizations with synthetic 
peptides, particularly MHC class I–binding epitopes, were performed in various trials. Since 
native epitopes have relatively low immunogenicity, various immunoaugmenting methods, 
including coadministration of adjuvants and cytokines [incomplete Freund adjuvant (IFA), 
IL-2, IL-12, or GM-CSF], were applied to achieve efficient immunization. Tumor regression 
in melanoma patients was observed in various clinical trials using melanocytespecific 
antigens such as MART-1 and gp100 and, in particular, the HLA high-binding modified 
peptide. Since CD4+ T cells appear to be directly and indirectly important in tumor 
rejection, combined immunization with both Th and CTL antigens is being attempted. 
Immunization with proteins containing multiple Th and CTL epitopes may be effective, 
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although production of recombinant GMP-grade proteins is costly, and modifications such 
as particle formation may be required for effective presentation of MHC class I–restricted 
epitopes. To facilitate peptide immunization in melanoma, coadministration of the anti-
CTLA4 antibody, which blocks regulatory T cells and negative feedback regulation of T-cell 
activation, was carried out. Although tumor regression along with autoimmune reactions 
was observed, augmentation of the immune response to the administered peptides was not 
observed in peripheral blood.24 In pancreatic cancer, intradermal immunization with the 
mutated K-ras peptides and GM-CSF resulted in the induction of a memory CD4+ T-cell 
response and prolonged survival, compared with nonresponders.15 Immunization with the 
MUC1 peptide and BCG resulted in augmented immune responses without tumor 
regression.22 Immunization with recombinant viruses or plasmids containing tumor antigen 
cDNA (DNA immunization) rather than peptide/proteins may be applied. In melanoma 
clinical trials, a generation of neutralizing antibodies against viral proteins appeared to 
interfere with the induction of immune response to tumor antigens following immunization 
with recombinant adenovirus and vaccinia virus.25 However, recent protocols using a 
recombinant fowlpox virus containing the modified gp100 cDNA or the ER signal sequence–
conjugated gp100-epitope minimal gene demonstrated frequent induction of tumor reactive 
T cells.26 Interestingly, tumor regression was observed in patients after subsequent 
administration of IL-2. 
Intramuscular immunization with the recombinant gp100 plasmids appeared to be 
insufficient to induce an antitumor T-cell response.27 DC are the most potent professional 
APC that can process antigens for both MHC class I and II pathways and activate both naive 
CD4+ T cells and CD8+T cells in vivo. In murine studies, immunization with DC pulsed 
with tumor antigens resulted in better antitumor effects than direct peptide administration. 
In immunization trials using DC pulsed with tumor lysates or synthetic peptides, tumor 
regression was observed in patients with various cancers, including melanoma, prostate 
cancer, colon cancer, and B-cell lymphoma.28 Although most clinical trials have used 
monocyte-derived DC, peripheral blood DC as well as CD34+ cell–derived DC have been 
used in some protocols.29 Antigen loading on DC using various antigens including RNA, 
cDNA, recombinant virusand cell-penetrating peptide conjugated proteins has also been 
exploited. DC fused with tumor cells and leukemia clone– derived DC have also been used 
in clinical trials. K-ras– specific T cells were detected in pancreatic cancer patients following 
multiple intravenous infusions of peptide-pulsed antigen presenting mononuclear cells 
obtained by leukapheresis, although no therapeutic effect in patients was observed. In 
addition, no tumor regression was observed following immunization with DC transfected 
with MUC1 cDNA. A decrease in tumor marker was observed in a patient with a pancreatic 
neuroendocrine tumor, following immunization with DC pulsed with autologous tumor 
lysates. Intratumoral administration of immature DC following intraoperative irradiation is 
currently being conducted in Japan. Thus far, any antitumor effects observed in these DC-
based clinical trials for pancreatic cancer are weak. Protocols for the optimal use of DC in 
immunotherapy, including the source of DC, kinds of tumor antigens, methods for 
maturation and antigen loading, site and schedule for administration, remain to be 
determined. Based on murine experiments, immunization with more immunogenic tumor 
cells that are modified using various techniques, including hapten conjugation, foreign 
antigen introduction, and transfection with various genes such as cytokines (eg, GM-CSF, 
IL-2, TNF-_, IFN-_, IL-4) have been employed in melanoma, prostate cancer, and lung 
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cancer. Strong antitumor effects, however, were not observed in the reported clinical trials. 
In pancreatic cancer, vaccination with GM-CSF transduced allogeneic pancreatic cancer cell 
lines along with adjuvant radiation and chemotherapy following surgical excision 
demonstrated possible benefit in disease-free survival, which appeared to be associated with 
the increase of postvaccination DTH responses against autologous tumor cells. 
4. Adoptive Immunotherapy with antitumor 
4.1 Immune cells 
Passive immunotherapy with large doses of activated antitumor lymphocytes was also 
employed since there was a possibility that active immunization would be insufficient to 
induce enough of an immune response to cause tumor regression in the immunosuppressed 
patient with a large tumor burden. Adoptive transfer of tumor-reactive T cells cultured from 
tumor-infiltrating lymphocytes, along with IL-2, resulted in a clinical response in melanoma 
patients.65 Adoptive transfer of EBV-specific T cells resulted in regression of EBV-associated 
lymphoma. Intraportal infusion of in vitro MUC1-stimulated T cells was performed in 
pancreatic cancer, yielding preliminary results that indicate inhibition of liver metastasis. 
Although the clinical use of tumor-reactive T cells was previously limited due to the 
difficulty in generating tumor-reactive T cells for most cancers, it is now possible to generate 
these cells from the PBMC of cancer patients by in vitro stimulation, using the identified 
tumor antigens.66 Tumor-reactive T cells from patients preimmunized with tumor antigens 
were generated more efficiently, which suggests that combined use of active and passive 
immunotherapies is ideal. One of the problems that arises from adoptive transfer of cultured 
T cells is the low efficiency of administered T cells in in vivo maintenance and accumulation 
in tumor tissues. However, it was recently reported that nonmyeloablative, 
lymphodepletive pre-treatment with cyclophosphamide and fludarabine resulted in 
extended persistence of administered tumor-reactive T cells in peripheral blood and tumor 
tissues and increased tumor regression, which may be due to suppression of patient 
immune responses or the need to make room for homeostatic proliferation of transferred 
lymphocytes.67 Adoptive immunotherapy with IL- 2–activated PBMC, LAK (lymphokine 
activated killer) cells displayed some antitumor effects when locally administered (ie, by 
intrapleural or intraarterial infusion) for lung or liver cancer. Intraportal administration 
following intraoperative irradiation in pancreatic cancer patients is reported to result in 
possible prolongation of survival68. 
Adoptive immunotherapy involves harvesting the patient’s peripheral blood T-
lymphocytes, stimulating and expanding the autologous tumour-reactive T-cells using IL-2 
and CD3-specific antibody, before subsequently transferring them back into the patient. 
Twelve patients with advanced pancreatic cancer who underwent resection, intraoperative 
radiotherapy and intraportal infusion of LAK cells with recombinant IL-2 had lower 
incidence of liver metastasis compared to controls (three of 12 vs ten of 15; p<0.05)69. There 
was no significant difference in overall survival, but more patients were alive three years 
later (36% vs none). 
Telomerase—Telomerase is a reverse transcriptase that contains a RNA template used to 
synthesise telomeric repeats onto chromosomal ends. Activation of telomerase and its 
maintenance of telomeres play a role in immortalisation of human cancer cells, as telomeres 
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shrink after each cell division 70. Telomerase activity is found in 92-95% of pancreatic cancers 
71-72, and is associated with increased potential of invasion and metastasis and poor 
prognosis 73-74. Upregulation of telomerase may also be responsible for the development of 
chemotherapy resistance 75. Adenovirus-mediated transduction of p53 gene inhibited 
telomerase activity in MIAPaCa-2, SUIT-2 and AsPC-1 cells, independent of its effect on 
apoptosis, cell growth and cycle arrest 76. Antisense to the RNA component of telomerase 
seemed to increase susceptibility of Panc-1 cells to cisplatin 77. Telomerase reverse 
transcriptase antisense oligonucleotide (hTERT-ASO) was found to inhibit the proliferation 
of BxPC-3 cells in vitro by decreasing telomerase activity and increasing apoptosis 78. 
Adoptive transfer of telomerase-specific T-cells was studied in a syngeneic pancreatic 
tumour mouse model 79. T-cells were produced in vitro by coculturing human lymphocytes 
with telomerase peptide-pulsed dendritic cells (DCs) or in vivo by injection of peptide with 
adjuvant into C57BL/6 mice. Animals treated with these T-cells showed significantly 
delayed disease progression. 
MUC1—Adoptive transfer of MUC1-specific cytotoxic T-lymphocytes (CTLs) was able to 
completely eradicate MUC1-expressing tumours in mice 80. Intraportal infusion of In  vitro 
MUC1-stimulated T-cells was performed in patients with pancreatic cancer, with 
subsequent inhibition of liver metastasis 81. In a study of eleven patients with lung 
metastases (from colorectal, pancreatic, breast, lung, or melanoma primaries), effector cells 
were generated in vitro using cultured DCs, synthetic peptide, peripheral blood 
lymphocytes, IL-2 and anti-CD3 antibody 82. A partial response of the lung metastases was 
observed in a patient with pancreatic cancer who received these cells stimulated with 
MUC1. 
4.2 Cytokines and immunomodulators 
TNFerade—TNF-ǂ is a multifunctional cytokine that has shown antitumour potency 83-85. 
TNFerade Biologic (TNFerade) is a replication-deficient adenovirus carrying the gene for 
human TNF-ǂ, regulated by a radiation-inducible promoter Early Growth Response (Egr-1). 
The latter would ensure maximal gene expression when infected tissue is irradiated 86. 
TNFerade was effective in combination with radiation in a number of human xenograft 
models, including glioma 87, prostate 88, oesophageal 89 and radiation-resistant laryngeal 
cancers 90. The multicentre phase II/III Pancreatic Cancer Clinical Trial with TNFerade 
(PACT) is currently ongoing and involved patients with locally advanced pancreatic cancer. 
Patients were given radiotherapy, 5-FU with or without CT-guided transabdominal injection 
of TNFerade. Preliminary data of 51 patients revealed that the one-year survival increased 
from  28% to 70.5% with the addition of TNFerade, with MS of 335 and 515 days 
respectively91. 
Virulizin—Virulizin (Lorus Therapeutics Inc.) is a biological response modifier obtained 
from bovine bile 92. It stimulates the expression of TNF-ǂ and activates macrophages, which 
subsequently activates natural killer cells via IL-12 93-94. Evidence exists to show that it also 
induces the production of IL-17E with resulting eosinophilia 95. 
In vivo studies showed that Virulizin significantly inhibited the growth of human pancreatic 
cancer xenografts (BxPC-3, SU 86.86 and MIAPaCa-2) in nude mice, as well as potentiated the 
antitumour effect of gemcitabine and 5-FU 96-97. A phase III trial was conducted to study the 
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effect of gemcitabine with or without Virulizin in 434 chemotherapy-naïve patients with 
advanced pancreatic cancer [341]. MS was not significantly better for the gemcitabine and 
Virulizin group compared to gemcitabine with placebo (6.3 vs 6 months). However for stage 
3 patients who received Virulizin in a salvage setting, a significant difference in survival was 
demonstrated (10.9 vs 7.4 months, p=0.017). 
4.3 IL-2 
Pancreatic cancer could thus constitute a paradigmatic example of neoplasia where tumor-
related variables and host immunosuppressive status have the same importance in 
determining an unfavourable prognosis. The severe suppression of anticancer immunity, 
which characterizes patients suffering from pancreatic cancer, is further aggravated by 
surgical treatment 98. In fact, it is known that surgery may inhibit anticancer immunity by 
provoking a postoperative decline in the absolute number of circulating lymphocytes 99-101, 
which play a fundamental role in generating an effective anticancer immune reaction; this is 
fundamentally an IL-2-dependent phenomenon 102. 
Surgery-induced immunosuppression could represent one of  the main factors responsible 
for relapse in cancer patients treated by radical surgery, by possibly promoting the growth 
of micro-metastases, already existing at the time of the surgical removal of the tumor . 
Previous clinical studies have shown that the immunosuppressive status occurring during 
the postoperative period is particularly severe in patients with pancreatic cancer  and this 
evidence could explain, at least in part, the high percentage of recurrences occurring in 
patients radically operated for cancer of the pancreas 103. At present, the only molecule 
which has been proven to correct the lymphocytopenia is IL-2, representing the main 
growth factor for lymphocytes, including T lymphocytes and natural killer (NK) cells 104 and 
the stimulation of lymphocyte proliferation would constitute the main mechanism 
responsible for the antitumor activity of IL-2 in the immunotherapy of cancer 105. Moreover, 
the preoperative administration of IL-2 for only few days prior to surgery was effective in 
preventing surgery-induced lymphocytopenia 106. In addition, the abrogation of surgery-
induced lymphocyte decline has been shown to improve the prognosis of patients with 
colorectal cancer in whether treated by radical or palliative surgery 107. The therapeutic 
impact of IL-2 presurgical administration remains to be better defined in gastric cancer 108, 
despite its efficacy in preventing the postoperative lymphocytopenia. Finally, the prevention 
of postoperative lymphocyte decline by IL-2 presurgical immunotherapy was associated 
with clear lymphocyte and eosinophil intratumoral infiltration in colorectal cancer patients, 
which, in contrast, was less evident in patients with gastric carcinoma. Preliminary clinical 
studies have suggested that preoperative injection of IL-2 may also prevent surgery-induced 
lymphocytopenia in patients with pancreatic cancer 109. According to previous 
investigations, IL-2 presurgical immunotherapy may also completely abrogate surgery-
induced lymphocytopenia also patients with pancreatic carcinoma, as well as previously 
described for both colorectal and gastric carcinomas. Moreover, in agreement with the 
clinical results previously reported for colorectal cancer patients and in contrast to those 
more controversially reported in gastric cancer, this study would suggest that a 
preoperative immunotherapy with IL-2 may improve the clinical course of the pancreatic 
cancer in terms of both FFPP and OS. Therefore, particularly because of its unfavourable 
prognosis, presurgical immunotherapy with IL-2 could represent a simple but effective 
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clinical strategy to improve the prognosis of pancreatic cancer patients undergoing 
macroscopical radical surgery. 
4.4 Allogeneic antigen-specific immunotherapy 
Allogeneic antigen-specific immunotherapies, nonmyeloablative SCT (minitransplant) and 
DLI (donor leukocyte infusion), are reported to have some antitumor effect [graft versus 
tumor (GVT)] on solid tumors, including RCC, breast cancer, and pancreatic cancer, in 
addition to haematological malignancies.110GVT effects were also observed in pancreatic 
cancer patients in minitransplant protocols conducted in Japan. Although the mechanisms 
of the antitumor effects, such as allogeneic responses to minor histocompatibility antigens 
(mHa), on hematological malignancies are well studied, they remain unclear with regard to 
solid tumors. One of the major problems in allogeneic treatment of the solid tumor is severe 
GVHD. Several strategies for the separation of GVT and GVHD have been developed for 
hematological malignancies. Whether this  separation is possible for solid tumors, however, 
is unclear. 
Was reported on the efficacy of adoptive immunotherapy (AIT) with cytotoxic T 
lymphocytes (CTLs), induced from autologous pancreatic tumors but not from AIT with 
LAK cells. Although these immunotherapies have a potential as alternative treatments for 
PC, the effects have been limited. 
Pancreatic cancer cells present an enormous challenge, as they are naturally resistant to 
current chemotherapy and radiation therapy. In addition, known pancreatic cancer antigens 
have generated relatively weak immune responses. This is probably due to a combination of 
mutations in oncogenes such as KRAS and tumour-suppressor genes such as TP53, 
CDKN2A, DPC4 (deleted in pancreas cancer 4), BRCA2 and ERBB2 (also known as 
HER2/neu), as well as overexpression of growth factors such as transforming growth factor-
 (TGF), interleukin-1 (IL-1), IL-6 and IL-8, tumour-necrosis factor-a (TNF), or vascular 
endothelial growth factor (VEGF), their receptors, or constitutive expression of multidrug-
resistant genes2, 3, 4, 5. Alternative therapeutic approaches are therefore urgently needed for 
this disease. 
Immune-based therapies aim to recruit and activate T cells that recognize tumour-specific 
antigens. In addition, recombinant monoclonal antibodies are being designed to target 
tumour-specific antigens — these would kill tumour cells either by direct lysis or through 
delivery of a conjugated cytotoxic agent. Both approaches are attractive for the treatment of 
pancreatic cancer for several reasons. First, these immune-based therapies act through a 
mechanism that is distinct from chemotherapy or radiation therapy, and represent a non-
cross-resistant treatment with an entirely different spectrum of toxicities. Second, through 
the genetic recombination of their respective receptors, the B cells and T cells of the immune 
system are capable of recognizing a diverse array of potential tumour antigens. In addition, 
both T and B cells can distinguish small antigenic differences between normal and 
transformed cells, providing specificity while minimizing toxicity. New insights into the 
mechanisms by which T cells are successfully activated and by which tumours evade 
immune recognition are driving the development of new combinatorial immunotherapy 
approaches. In addition, recent advances in gene-expression analysis have allowed for the 
identification of new pancreatic targets, including candidate tumour antigens that might 
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serve as T-cell and antibody targets. These advances now make it possible to exploit the 
immune system in the fight against pancreatic cancer. 
4.5 Targeting signalling molecules 
By the time that patients are diagnosed with pancreatic cancer, the tumour has typically 
progressed and invaded adjacent structures. Perineural invasion, metastasis to lymph nodes 
and liver, and an intense DESMOPLASTIC STROMAL REACTION are commonly observed. 
A range of signalling pathways, including epidermal growth factor receptor (EGFR) and the 
PI3K–AKT–mTOR–S6K cascades, are known to mediate pancreatic tumour growth and 
progression111n addition, new blood-vessel formation (angiogenesis) is required for the 
growth of primary pancreatic tumours and is essential for metastasis. In pancreatic tumours, 
this process is probably regulated by fibroblast growth factor, platelet-derived endothelial-
cell growth factor and VEGF family members. In fact, several pancreatic-cancer-associated 
genes have been linked to angiogenesis. DPC4 upregulates VEGF expression, and mutated 
KRAS expression is associated with increased micro-vessel density112. 
Monoclonal antibodies that target a range of these pathways have demonstrated efficacy in 
preclinical models113-115dition, monoclonal antibodies that target EGFR and VEGF receptor 
have been tested in patients with a range of cancers, including pancreatic cance115,117hough 
these antibodies have demonstrated only modest results as single agents, the pathways they 
affect are also candidate targets for immune intervention. 
Preclinical evidence has also shown that specific inhibitors of these signalling pathways can 
also increase immune activation. For example, VEGF is a key inhibitor of pro-inflammatory 
cytokines as well as dendritic-cell maturation, and it can also directly inhibit T-cell 
development. So antibodies that block signalling by this growth factor can promote 
antitumour immune responses. Furthermore, downregulation of the ERBB-receptor-family 
members with drugs such as herceptin promotes tumour-antigen presentation by HLA class 
I molecules, improving the potential for T-cell recognition and lysis118onoclonal antibodies 
that target these signalling pathways are now being developed for clinical trials as agents 
that potentially synergize with other immune-based approaches, including vaccines. 
4.6 Vaccines against pancreatic tumour antigens 
To develop the ideal vaccine for pancreatic cancer, the following wish list would probably 
need to be fulfilled. First, specific cell-surface proteins must be identified that are that are 
crucial in the cancer growth or progression pathway and are unique to pancreatic cancer 
tumours. Second, these tumour-exclusive proteins should be shown to elicit a vigorous 
tumour-protein-specific immune response. Third, the best carrier to deliver the appropriate 
immunogenic tumour proteins should be identified. Fourth, molecules that are immune 
stimulatory as well as molecules that can abrogate the natural immune-inhibition signalling 
that is seen in pancreatic cancer should be identified to enhance the immune response. Fifth, 
additional synergistic immune help should be identified (for example, antibodies or ex vivo 
tumour-reactive T cells). Several proteins, such as carcinoembryonic antigen (CEA), mutated 
KRAS, mucin-1 (MUC1) and gastrin, have in fact been identified to be specifically 
overexpressed in most pancreatic cancers119-125 antigens were identified over 10 years ago 
using various methods to analyse gene expression in cancer cells. Vaccines and antibodies 
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designed to target these antigens have been tested in early-phase clinical trials126-131hese 
antigens are known to have weak inherent immune potential, various immune-modulating 
agents were co-administered, including granulocyte–macrophage colony-stimulating factor 
(GM-CSF), and interleukin-2 (IL-2). So far, a few studies have demonstrated post-
vaccination immune responses to the relevant peptides or whole proteins. Significant 
clinical responses have not yet been observed. This might be due to the lack of pooling of 
the right antigens, to the existence of host mechanisms of immune tolerance, the inability of 
the relevant immune cells to effectively localize to the sites of disease, or a combination of 
these factors. 
Vaccination involves administering an antigen that is unique for a particular type of tumour 
with the aim of stimulating tumour-specific immunity. Antigens could be delivered in the 
form of DNA or peptide, as well as tumour cells or antigen-pulsed DCs. Additional 
synergistic help is added to elicit a more vigorous and effective immune response, such as 
cytokines and immunostimulating adjuvants. 
Whole-Cell—GM-CSF is one of a few cytokines that has shown significant antitumour effect 
in vivo [342]. It is an important growth factor for granulocytes and monocytes, and has a 
crucial role in the growth and differentiation of DCs, the most potent antigen-presenting 
cells (APCs) for triggering immune response. In vivo growth of AsPC-1 cells, retrovirally 
transduced with the GM-CSF gene, was inhibited and associated with increased survival of 
the nude mice, even in the mature T-cell-deficient condition 132. Jaffee et al. conducted a 
phase I study using allogeneic GM-CSF-secreting whole-cell tumour vaccine for pancreatic 
cancer 133. This is based on the concept that the localisation of GMCSF in the implanted 
tumour environment together with the shared tumour antigen expressed by the primary 
cancer would effectively induce an antitumour immune response. In this study two 
pancreatic cancer cell lines (PANC 10.05 and PANC 6.03) were used as the vaccine, both 
genetically modified to express GM-CSF. 14 pancreatic cancer patients who had undergone 
pancreaticoduodenectomy eight weeks prior were given variable doses of the vaccine 
intradermally. Three of the eight patients who received ≥10 × 107 vaccine cells developed 
postvaccination delayed-type hypersensitivity (DTH) responses associated with increased 
disease free survival time, and remained disease-free for longer than 25 months after 
diagnosis. Side effects were mainly limited to local skin reactions at the site of vaccination. 
In a recently completed phase II study of 60 patients with resected pancreatic 
adenocarcinoma, patients received five treatments of 2.5 × 108 vaccine cells, together with 5-
FU and radiotherapy134. The reported MS was 26 months, with a one- and two-year 
survival of 88% and 76% respectively. 
4.7 Peptide and DNA 
 Ras: As described earlier, mutated ras is highly prevalent in pancreatic cancer. A phase 
II study was done using mutant ras peptide-based subcutaneous vaccine in 12 cancer 
patients (five with fully resected pancreatic and seven with colorectal cancers). Five out 
of 11 patients showed showed ≥1.5 fold increase in interferon-Ǆ (IFN-Ǆ) mRNA copies 
in peripheral blood mononuclear cells. The pancreatic cancer patients showed a disease-
free survival of >35.2 months and post-vaccination survival of >44.4 months 135. 
Gjertsen et al tested an intradermal vaccine of APCs loaded ex vivo with synthetic ras 
peptide corresponding to the ras mutation found in the patient’s tumour 136. In this 
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phase I/II study of five patients with advanced pancreatic cancer, two of them showed 
induced immune response. They also studied ras peptide in combination with GM-CSF 
in a phase I/II trial involving 48 patients with pancreatic adenocarcinoma of variable 
stage 137. Peptide-specific immunity was induced in 58% of patients. Of patients with 
advanced disease, those who responded to treatment showed increased survival 
compared to non-responders (148 and 61 days respectively; p=0.0002). 
As IL-2 is involved in T-cell-mediated immune response, a vaccine consisting of mutant ras 
peptide in combination with GM-CSF and IL-2 was tested in a phase II trial of 17 patients 
with advanced cancers (14 colorectal, one non-small cell lung and two pancreatic cancers) 
138. Of the six patients with positive immune response (by means of IFN-Ǆ mRNA copies), 
the MS and the median PFS were 39.9 and 17.9 months compared to 18.5 and 15.6 months 
for nonresponders, respectively. Grade III toxicities led to IL-2 dose reduction in three of the 
patients. 
 CEA and MUC1: Carcinoembryonic antigen (CEA) glycoprotein is expressed at a low 
level in normal colonic epithelium but is overexpressed in many malignant diseases, 
including those of the colon, rectum, stomach and pancreas (85-90%) 139. Its serum 
level is sometimes used as a marker for the diagnosis of pancreatic cancer, with a 
sensitivity of 25-40% and a specificity of 70-90% 140-141. 
To boost MUC1-specific immune response, a vaccine composed of MUC1 peptide and 
SBAS2 adjuvant was tested in a phase I study 142. There was an increase in the percentage 
of CD8+ T-cells and MUC1-specific antibody (some developed IgG). Hope for the CEA or 
MUC1 vaccine was nevertheless crushed when a phase III trial of 255 patients using 
PANVAC-VF (vaccine consisted of recombinant vaccinia and fowlpox viruses coexpressing 
CEA, MUC-1 and TRICOM) failed to improve overall survival compared to palliative 
chemotherapy or best supportive care. 
 Gastrin: G17DT (Gastrimmune or Insegia) is an immunoconjugate of the amino-
terminal sequence of gastrin-17 (G-17) linked by means of a spacer peptide to 
diphtheria toxoid. Given intramuscularly it induces the formation of antibodies that can 
neutralise both amidated-G-17 and the precursor glycine-extended G17 143. In a phase 
II study of 30 patients, 67% mounted an antibody response. A significantly higher 
response (82%) was achieved in those given the highest dose of 250μg compared to 46% 
in the 100μg group. MS was significantly higher (217 days) for the antibody responders 
compared to non-responders (121 days; p=0.0023). 
When used as a monotherapy for patients with advanced pancreatic cancer unwilling or 
unsuitable to take chemotherapy, MS was 151 compared to 82 days in the placebo group 
(p=0.03) [360]. G17DT was subsequently tested in a phase III trial with or without 
gemcitabine in 383 untreated patients with locally advanced, recurrent or metastatic 
pancreatic adenocarcinoma. This unfortunately showed that the addition of G17DT did not 
improve overall survival or secondary endpoints Increasing -17 antibody titre levels in a 
subset of patients, however, were associated with increased survival. 
 Mesothelin: Thomas and colleagues provided the first direct evidence, by using 
mesothelin epitopes, that pancreatic cancer-specific CD8+ T-cell response can be 
generated via crosspresentation by an approach that recruits APCs to the vaccination 
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site 144. Gaffney et al studied the mesothelin DNA vaccine in combination with the 
anti-glucocorticoid-induced TNF receptor antibody (anti-GITR) in mice with syngeneic 
mesothelin-expressing pancreatic cancer 145. 50% of animals treated with mesothelin 
were tumour-free 25 days after tumour injection compared to 0% of non-treated mice. 
This increased to 94% with the addition of anti-GITR. The agonist anti-GITR served to 
enhance T-cell-mediated response of the vaccine 146-147. 
 Telomerase: The telomerase peptide vaccine GV1001 was tested in a phase I/II study of 
48 patients with unresectable pancreatic cancer 148. They received intradermal injection 
in combination with GM-CSF. Immune responses, as measured by DTH skin reaction 
and T-cell proliferation in vitro, were demonstrated in 24 of 38 evaluable patients, with 
the highest percentage (75%) in the intermediate dose group. MS for this group was 
significantly longer at 8.6 months, and one-year survival was 25%. GV1001 was given to 
patients in a phase I trial using imiquimod as an adjuvant149. Imiquimod acts by 
binding to Toll-like receptor 7 on immune cells, resulting in the production of cytokines 
such as IFN-ǂ, IFN-ǃ and IL-12. Immune response was found in up to six (46%) of 13 
evaluable patients. 
 Survivin: Survivin-specific CTLs were isolated from pancreatic cancer patients and 
these could lyse pancreatic carcinoma cell lines in vitro 150. Vaccination with survivin 
DNA prolonged survival in murine pancreatic and lymphoma tumour models, 
associated with slower tumour growth and increased lymphocyte infiltration . Survivin 
peptide was tested in a patient with gemcitabine refractory pancreatic cancer . Whilst 
on treatment he had complete remission of liver metastases after six months. However 
when he was weaned from the vaccination he developed recurrent disease. Vaccine-
induced immune activity was detected by IFN-Ǆ enzyme-linked immunospot 
(ELISPOT) assay. 
Antigen-pulsed DCs—Antigen-specific T-cell responses are initiated by DCs. They capture 
antigens secreted or shed by tumour cells and present peptides in association with the MHC 
class I and II molecules. This results in the expression and upregulation of cytokines and 
costimulatory molecules which in turn stimulate CD4+ and CD8+ T-cells to mount an 
antitumour response. As such DCs that carry the tumour antigen of interest is an ideal 
adjuvant in cancer immunotherapy. 
 MUC1: In a phase I/II trial, human autologous DCs transfected with MUC1 cDNA 
were used as a vaccine for ten patients with advanced breast, pancreatic or papillary 
cancer 151. Four patients showed a two- to ten-fold increase in the frequency of mucin-
specific IFN-Ǆ-secreting CD8+ T-cells, suggesting an immune response. In a phase 1b 
study, eight patients with pancreatic or biliary tumours were vaccinated with DCs 
pulsed with MUC1 152.  
As discussed previously, monoclonal antibodies have so far been the most successful form 
of immunotherapy clinically. They are being used as diagnostic tools, prognostic indicators, 
and for the treatment of many cancers. Advantages include their specific targeting of 
tumour cells while sparing normal tissue, their relative ease of administration, and their low 
toxicity profile. The major disadvantages include the absence of T-cell activation, which 
therefore precludes T-cell-mediated cytotoxic killing and the generation of memory immune 
responses. In addition, a potential limiting factor in its use involves tumour heterogeneity. 
Specifically, all tumour cells within a proliferating mass might not express the antigen that is 
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being targeted. Inhibitors to EGFR and to VEGF have been tested in combination with 
gemcitabine and are currently in Phase III trials either with other approaches have used 
dendritic cells as the carrier of the antigen of interest. To date, CEA and MUC1 antigens 
have been among the initial antigens tested, with mixed results153-154 se of adoptively 
transferred pancreatic-cancer-specific T cells has been proposed to be another opportunity 
to augment the immune response. Although this strategy has been promising preclinically, 
and has been used with some success in melanoma, there have not been any clinical trials in 
pancreatic cancer so far.  
A current limitation to the development of vaccines for pancreatic cancer has been the inability 
to correlate in vitro measures of antitumour immunity with in vivo responses. Post-vaccination 
DTH responses to autologous tumour are a potential useful surrogate, but this approach is not 
ideal. At present, it is technically challenging to produce sufficient quantity and purity of 
autologous tumour material for testing, as tumours vary in their composition of tumour cells 
versus other cell types between patients. Although other biological end points, such as an 
antibody response or in vitro CYTOLYTIC T LYMPHOCYTE (CTL) ASSAY against a vaccine-
delivered tumour antigen (or antigens), have been measured and provide important 'proof of 
concept' data, these end points have also not been demonstrated to be predictors of traditional 
clinical end points, including tumour response and survival benefit. 
It is difficult to assess whether the lack of improved survival after immunotherapy is due to 
inefficient antigen delivery, which could result in ineffective immunization, inappropriate 
selection of antigen targets, or both. As discussed above, there are formidable barriers to 
inducing an antitumour immune response, even when the vaccine itself is potent enough to 
reduce significant cancer burdens in more immunogenic tumour systems. Effective 
immunization will therefore require the targeting of relevant pancreatic tumour antigens 
using optimized antigen-delivery systems with immune-stimulating cytokines, in sequence 
with other therapeutic interventions that alter immune checkpoints in the tumour 
microenvironment, such as inhibitors to regulatory molecules on T cells (for example, 
antibody to CD152/CTLA4). 
5. New immunotherapy targets 
The inability of previously tested antigens (including CEA, KRAS, MUC1 and gastrin) to 
induce immune-specific responses underscores the challenge to identify more relevant 
immunogenic targets. Indeed, these antigens were chosen only because they were 
overexpressed or had altered expression in pancreatic tumours, and not because they had 
been shown to be immunogenic. Therefore, there might be additional as-yet-unidentified 
antigens that might be more immunogenic for inducing effective immunity against 
pancreatic cancers. How will such new candidate pancreatic cancer antigens be discovered? 
Two methods are routinely used in an attempt to identify new targets. The first method, 
serological analysis of recombinant tumour cDNA expression libraries (SEREX), uses serum 
to screen phage-display libraries prepared from tumour cells to identify candidate antigen 
targets that have elicited both humoral and cell-mediated immune responses in cancer 
patients. This method has identified coactosin-like protein (an actin-filament-binding 
protein that interacts directly with 5-liopoxygenase and has an important role in cellular 
leukotriene synthesis) as a potential pancreatic cancer target antigen. This protein seems to 
be recognized by antibody and T-cell responses in patients with pancreatic cancer155. 
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The second method uses tumour-specific T cells that have been isolated from patients with 
pancreatic cancer to screen cDNA libraries prepared from autologous tumour cells. This 
method requires the isolation and culture of tumour-specific T cells, along with tumour 
cells, from patients with pancreatic cancer and is a technically challenging approach. This 
approach has been most successful in identifying melanoma-associated antigens156. 
A relatively newer, more promising method of tumour-antigen identification is the use of 
the patient's lymphocytes to evaluate proteins that are found to be differentially expressed 
by pancreatic cancer157-158 approach has several advantages. First, it allows for a rapid screen 
of a large number of candidate antigens but requires the isolation from patients of only a 
few lymphocytes, which are limited in availability. Second, this approach is not dependent 
on the availability of autologous tumour cells, which are difficult to isolate in large enough 
numbers for generating cDNA libraries. Third, this approach can be used to identify tumour 
antigens that are expressed by any HLA type, allowing for the generalization of this 
approach to most patients. Finally, this approach has the potential to rapidly identify 
'immune relevant' antigens, as it uses immunized lymphocytes from patients vaccinated 
with a whole-tumour-cell vaccine approach who ideally have demonstrated clinical 
evidence of immune activation following vaccination. So this method provides the best 
insurance that the antigens identified are ones that the patient's immune system is reacting 
to after immunization. 
As additional 'immune relevant' pancreatic tumour antigens are identified, the next 
significant challenge lies in developing strategies to improve the in vivo delivery of these 
antigens to APCs and thereby allow effective antigen processing and presentation, and 
subsequent activation of a potent antitumour immune response. DCs are now accepted as 
the most efficient APCs in B- and T-cell activation. Several clinical trials have tested ex vivo 
expanded and primed DCs as a vaccine approach. However, these studies have revealed the 
difficulty in reliably producing phenotypically mature DCs for clinical testing, as only 
mature DCs are capable of efficiently presenting antigens to T cells. If an antigen is not 
presented in the proper context by mature DCs, immune downregulation or tolerance can 
occur. It has been shown in animal models that immature DCs induce T-cell tolerance. As an 
alternative to DC-based delivery, recombinant viral- and bacterial-vector delivery systems 
are currently under development or are already undergoing clinical testing. The use of 
modified viral particles or targeted bacteria to deliver tumour antigens to the immune 
system is based on the innate ability of the agent to efficiently infect APCs in vivo. Early 
approaches have included viruses such as vaccinia 159,160 er, the use of immunogenic vectors 
in cancer patients who have been previously exposed to a similar vector often induces 
vigorous immune responses against the vector before effective priming against the tumour 
antigen can occur. As such, other viral particles and bacterial delivery systems are currently 
nearing or are already undergoing clinical development for the treatment of pancreatic 
cancer.  
6. Future directions 
The limitations of currently available therapy for pancreatic cancer are more clearly exposed 
as we begin to appreciate the molecular changes behind the complex transformation of 
normal pancreatic ductal cells into frank pancreatic cancers, and the mechanisms of 
pancreatic cancer resistance to traditional anticancer modalities. It is clear that the most 
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effective therapy will require a combined approach incorporating the best targeted 
interventions taken from each respective modality. Preclinical models have already revealed 
the synergy between immunotherapy and other targeted therapeutics, such as inhibitors of 
VEGF and EGF signalling. These combinations are about to be tested in patients with 
pancreatic cancer. 
Pancreatic cancer remains one of the most resistant cancers to traditional forms of therapy. 
Until techniques for early detection can be developed, most patients will continue to present 
with incurable disease. The pancreatic cancer research community is committed to 
developing new therapies for this disease. Pancreatic cancer patients and their families, 
through a number of national pancreatic cancer non-profit organizations such as Pancreas 
Cancer Action Network have organized to support this effort. It is crucial that we move 
forward with scientifically driven innovative therapies, as the empirical approaches have 
failed. Recent developments in the design of mouse models that recapitulate early pre-
invasive genetic changes in KRAS activation, inactivation of CDKN2A, TP53 and SMAD4 
tumour-suppressor genes should provide the opportunity to test such approaches in a 
timely manner161,162. 
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